Rabbit Polyclonal TRIM47 Antibody

+ +

•  

   
     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P03883(SLC1A2 Antibody) at dilution 1/20. (Original magnification: ×200)    

•  

   
     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P03883(SLC1A2 Antibody) at dilution 1/20. (Original magnification: ×200)    

The TRIM47 (Tripartite Motif-containing 47) antibody is a tool used to study the TRIM47 protein, a member of the TRIM family characterized by conserved RING, B-box, and coiled-coil domains. TRIM proteins are involved in diverse cellular processes, including ubiquitination, immune regulation, and cancer progression. TRIM47. specifically, has gained attention for its oncogenic roles. Studies link its overexpression to tumorigenesis in cancers like glioma, lung, and colorectal cancer, where it promotes cell proliferation, migration, and chemoresistance by modulating pathways such as NF-κB, MAPK, or Wnt/β-catenin. It may also interact with key proteins like β-catenin or p65 to drive oncogenic signaling.

TRIM47 antibodies, typically monoclonal or polyclonal, are generated in hosts like rabbits or mice using immunogenic peptide regions of the protein. They enable detection of TRIM47 expression via techniques like Western blot, immunohistochemistry (IHC), or immunofluorescence (IF). Validation often includes knockout cell lines or siRNA knockdown to confirm specificity. Researchers use these antibodies to explore TRIM47's clinical relevance, such as its correlation with poor prognosis, metastatic potential, or therapeutic resistance. Additionally, TRIM47 antibodies aid in mechanistic studies to dissect its role in ubiquitination-dependent or -independent processes. As TRIM47 emerges as a potential biomarker or therapeutic target, its antibody remains critical for both basic research and translational applications in oncology.